Drug Profile
XG 104
Alternative Names: XG-104Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Xigen
- Class Eye disorder therapies
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes
- No development reported Unspecified
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Unspecified in Switzerland
- 28 Dec 2018 No recent reports of development identified for phase-I development in Dry-eyes in France (IV, Infusion)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Dry-eyes(In volunteers) in France (Topical)